Latest news with #StacyBeske
Yahoo
20-05-2025
- Health
- Yahoo
Philips launches 3D imaging catheter in Europe
Philips has launched the VeriSight Pro 3D intracardiac echocardiography (ICE) catheter on the European market. Able to integrate with Philips' EPIQ ultrasound systems, which in turn work with its Azurion image-guided therapy platform, Philips said VeriSight complements its existing structural heart disease ecosystem in Europe. The Dutch healthtech giant added that alongside tools such as EchoNavigator, VeriSight's introduction in Europe means it can now offer an end-to-end solution for clinicians performing procedures such as tricuspid and mitral valve repair and replacement, atrial septal defect closure, and left atrial appendage occlusion. Comprised of a miniaturised ultrasound probe embedded at the tip of a thin, steerable catheter, VeriSight provides physicians with real-time 3D and 2D imaging directly inside the heart, with the catheter intended to help physicians perform procedures with 'greater clarity'. The catheter also features xPlane and iRotate technologies, allowing physicians to visualise two imaging planes simultaneously and digitally adjust views without physically repositioning the catheter tip, thereby enabling more precise imaging assessment with fewer deployment steps, Philips said. According to Philips, with introduction via the femoral vein, VeriSight also reduces the need for general anaesthesia and recovery time in post-anaesthesia care units (PACU), which can shorten hospital stays and reduce costs. VeriSight received clearance from the US Food and Drug Administration (FDA) in September 2020 ahead of an initially limited market launch in the country in 2021. The first procedure completed with the catheter in the US occurred in July 2021. Stacy Beske, business leader of image-guided therapy devices at Philips, called VeriSight's Europe launch an 'important milestone' that would help more patients benefit from image-guided, minimally invasive heart procedures, while supporting care teams with integrated solutions that 'adapt to the way they work'. Beske adds: 'VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience.' Research by the European Commission (EC) indicates that structural heart disease (SHD) is a significant healthcare burden in Europe and is projected to rise from 14 million people with SHDs in 2020 to exceed 20 million by 2040, mostly due to the ageing population. Transcatheter aortic valve replacement (TAVR) procedures for treating SHD represent a significant growth area in the SHD treatment landscape. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. Key player Edwards Lifesciences, which holds more than a 60% share of the US TAVR market, as per GlobalData's US Healthcare Facility Invoicing Database, recently received FDA approval for its Sapien 3 TAVR platform received FDA approval for treating asymptomatic aortic stenosis patients. According to GlobalData analysis, however, Medtronic's Evolut TAVR system could be set to disrupt the US market dynamic following the release of data suggesting that Evolut could prove to be a 'superior product'. "Philips launches 3D imaging catheter in Europe" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
19-05-2025
- Business
- Yahoo
Philips Expands 3D Heart Imaging with VeriSight Pro in Europe
On May 19, Koninklijke Philips N.V. (NYSE:PHG) introduced VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe, enhancing real-time heart imaging without general anesthesia. Building on its success in the U.S., VeriSight Pro offers high-resolution 2D and 3D visualization, aiding transcatheter valve repair and left atrial appendage closure procedures. A doctor in a lab coat holding a healthcare solution in their hands. "With VeriSight Pro 3D ICE, we now have the ability to see detailed cardiac anatomy from inside the heart in real time," said Prof. Dr. Jörg Hausleiter of LMU Munich, emphasizing its role in streamlining workflows and making complex procedures more accessible. Traditional imaging methods, like transesophageal echocardiography (TEE), require general anesthesia, extended room time, and additional staff. VeriSight Pro's miniaturized ultrasound probe—just 3 millimeters in diameter—delivers real-time imaging inside heart chambers via a thin, steerable catheter, reducing recovery times and hospital stays. "VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience," said Stacy Beske, Philips' Business Leader of Image-Guided Therapy Devices. The catheter integrates with Philips' EPIQ ultrasound systems and Azurion image-guided therapy platform, supporting procedures like mitral valve repair and atrial septal defect closure. Philips will showcase VeriSight Pro at EuroPCR 2025 in Paris (May 20–23) through physician-led symposiums, hands-on training, and immersive VR experiences. While we acknowledge the potential of Koninklijke Philips N.V. (NYSE:PHG) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PHG and that has 100x upside potential, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
19-05-2025
- Health
- Hamilton Spectator
Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures
May 19, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe. Building on its success in the United States, VeriSight Pro brings real-time 3D imaging directly inside the heart, helping physicians perform procedures with greater clarity — without the need for general anesthesia. Designed for procedures such as transcatheter valve repair and left atrial appendage closure, VeriSight Pro offers high-resolution 2D and 3D visualization directly within the heart chambers. This enables confident clinical decision-making in structural heart and electrophysiology interventions, while removing the need for general anesthesia and associated risks. 'With VeriSight Pro 3D ICE, we now have the ability to see detailed cardiac anatomy from inside the heart in real time,' said Prof. Dr. Jörg Hausleiter, Ludwig-Maximilians-Universität (LMU) Munich, Germany. 'This helps streamline our workflows and makes complex procedures more accessible to patients who may not tolerate more invasive imaging approaches.' Addressing structural heart disease with less burden on patients and hospitals Structural heart disease is a growing challenge across Europe, with increasing volumes of transcatheter valve repair and closure procedures. Today, many of these are supported by transesophageal echocardiography (TEE), which often requires general anesthesia, additional staff, and extended room time. In contrast, 3D ICE imaging provides detailed visualization from within the heart through a catheter introduced via the femoral vein, reducing the need for general anesthesia and recovery time in the Post-Anesthesia Care Unit (PACU), which can shorten hospital stays and lower costs. VeriSight Pro is a pioneering innovation: a miniaturized ultrasound probe, approximately 3 millimeters in diameter, embedded at the tip of a thin, steerable catheter. This tiny device can be navigated through the vascular system and into the heart chambers, where it delivers high-quality 2D and 3D images in real time. Imaging the heart from within, with control over the scan angle, opens entirely new possibilities for guiding structural heart interventions. Physicians can assess anatomy, guide device placement, and confirm procedural results — all from a single access point, and without the need for more invasive imaging techniques. As the first ICE catheter to miniaturize the same 3D imaging technology used in TEE, VeriSight Pro helps address key barriers in delivering efficient, scalable care — from patient tolerance to resource availability in interventional suites. 'VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience,' said Stacy Beske, Business Leader of Image-Guided Therapy Devices at Philips. 'Its availability in Europe is an important milestone in helping more patients benefit from image-guided, minimally invasive heart procedures, while supporting care teams with integrated solutions that adapt to the way they work.' Part of an integrated portfolio for structural heart care VeriSight Pro is part of Philips' structural heart disease ecosystem, seamlessly integrating with Philips' EPIQ ultrasound systems, which in turn integrate with the Azurion image-guided therapy platform. Combined with tools such as EchoNavigator, Philips offers an end-to-end solution for clinicians performing procedures such as tricuspid and mitral valve repair and replacement, atrial septal defect closure, and left atrial appendage occlusion. The catheter's unique features — including xPlane and iRotate technologies — allow physicians to visualize two imaging planes simultaneously and digitally adjust views without physically repositioning the catheter tip. These capabilities enable precise assessment and device deployment with fewer imaging steps. Showcasing 3D ICE in action at EuroPCR 2025 Philips will highlight VeriSight Pro and its role in structural heart interventions at EuroPCR 2025 in Paris, May 20–23. Key activities include: These sessions will offer clinicians an in-depth look at how 3D ICE is being applied in real-world structural heart procedures — from imaging protocols to workflow integration and clinical outcomes. A complete and detailed overview of sessions can be found here: . For further information, please contact: Joost Maltha Philips Global External Relations Tel.: +31 6 10 55 8116 E-Mail: About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at . Attachment
